天然免疫调节剂治疗COVID-19的可行性——全面分析及未来建议
本文综述了具有免疫调节潜力的天然化合物在COVID-19患者中的临床试验现状与结果,以及其体内研究结果。临床试验显示,多种天然免疫调节剂可显著改善COVID-19患者症状(发热、咳嗽、咽痛、呼吸困难),缩短住院时间,减少补充氧疗需求,改善临床结局(尤其是乏力),并消除急性肺损伤和急性呼吸窘迫综合征。体内研究显示天然免疫调节剂可降低多种促炎细胞因子。作者认为,在小规模临床试验中有效、安全且耐受良好的天然免疫调节剂值得开展大规模试验以用于治疗COVID-19感染;尚未进行临床测试的化合物也应开展临床试验以确定其有效性和安全性。
要点
- 多种天然免疫调节剂(如白藜芦醇、槲皮素、姜黄素、小檗碱、木犀草素等)可抑制促炎细胞因子和趋化因子。
- 临床试验中,若干天然免疫调节剂显著改善COVID-19患者症状,包括发热、咳嗽、咽痛和呼吸困难。
- 这些化合物缩短了住院时间,减少了补充氧疗需求,并改善了临床结局,尤其是乏力。
- 天然免疫调节剂消除了急性肺损伤和急性呼吸窘迫综合征。
- 在小规模临床试验中有效、安全且耐受良好的天然免疫调节剂,有必要开展大规模试验以用于治疗COVID-19感染。
适用人群与场景
- COVID-19患者,包括免疫功能失调和免疫受损者,此类患者感染SARS-CoV-2后出现急性呼吸窘迫综合征、脓毒症、多器官衰竭等严重并发症。
红旗征与不能漏的情况
- 免疫功能失调和免疫受损的COVID-19患者出现急性呼吸窘迫综合征、脓毒症、多器官衰竭等严重并发症。
研究设计与关键结果
- 综述分析了具有免疫调节潜力的天然化合物在COVID-19患者中的临床试验现状与结果,以及其体内研究结果。
- 临床试验中,若干天然免疫调节剂显著改善COVID-19患者症状(发热、咳嗽、咽痛、呼吸困难),缩短住院时间,减少补充氧疗需求,改善临床结局(尤其是乏力),并消除急性肺损伤和急性呼吸窘迫综合征。
- 体内研究显示,天然免疫调节剂可降低多种促炎细胞因子。
- 论文还讨论了多种尚未进行临床试验的强效天然免疫调节剂。
证据类型、等级与局限
- 证据类型:综述。
- 在小规模临床试验中有效、安全且耐受良好的天然免疫调节剂,有必要开展大规模试验以用于治疗COVID-19感染;尚未进行临床测试的化合物应开展临床试验以确定其有效性和安全性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在小规模临床试验中有效、安全且耐受良好的天然免疫调节剂值得开展大规模试验以用于治疗COVID-19感染。
- 作者认为,尚未进行临床测试的化合物应开展临床试验以确定其在COVID-19患者治疗中的有效性和安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The COVID-19 pandemic has inflicted millions of deaths worldwide. Despite the availability of several vaccines and some special drugs approved for emergency use to prevent or treat this disease still, there is a huge concern regarding their effectiveness, adverse effects, and most importantly, their efficacy against the new variants. A cascade of immune-inflammatory responses is involved with the pathogenesis and severe complications with COVID-19. People with dysfunctional and compromised immune systems display severe complications, including acute respiratory distress syndrome, sepsis, multiple organ failure etc., when they get infected with the SARS-CoV-2 virus. Plant-derived natural immune-suppressant compounds, such as resveratrol, quercetin, curcumin, berberine, luteolin, etc., have been reported to inhibit pro-inflammatory cytokines and chemokines. Therefore, natural products with immunomodulatory and anti-inflammatory potential could be plausible targets to treat this contagious disease. This review aims to delineate the clinical trials status and outcomes of natural compounds with immunomodulatory potential in COVID-19 patients along with the outcomes of their in-vivo studies. In clinical trials several natural immunomodulators resulted in significant improvement of COVID-19 patients by diminishing COVID-19 symptoms such as fever, cough, sore throat, and breathlessness. Most importantly, they reduced the duration of hospitalization and the need for supplemental oxygen therapy, improved clinical outcomes in patients with COVID-19, especially weakness, and eliminated acute lung injury and acute respiratory distress syndrome. This paper also discusses many potent natural immunomodulators yet to undergo clinical trials. In-vivo studies with natural immunomodulators demonstrated reduction of a wide range of proinflammatory cytokines. Natural immunomodulators that were found effective, safe, and well tolerated in small-scale clinical trials are warranted to undergo large-scale trials to be used as drugs to treat COVID-19 infections. Alongside, compounds yet to test clinically must undergo clinical trials to find their effectiveness and safety in the treatment of COVID-19 patients.
参考来源
- Akter R, Rahman MR, Ahmed ZS, et al. Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations. Heliyon. 2023. PMID: 37366526. doi:10.1016/j.heliyon.2023.e17478
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。